Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716274 | 0.90 | OPRM1 (0.44) | OPRM1ALOX5HDAC6RCE1SLC6A2 | |
| SCHEMBL720495 | 0.80 | TEAD4 (0.34) | RCE1ABL1RIN1 | |
| SCHEMBL718796 | 0.77 | RCE1 (0.53) | OPRM1RCE1 | |
| SCHEMBL717386 | 0.74 | GCG (0.46) | OPRM1RCE1 | |
| SCHEMBL717719 | 0.74 | TP53 (0.36) | HDAC6 | |
| SCHEMBL721467 | 0.74 | SSTR4 (0.35) | HDAC6RCE1ABL1RIN1 | |
| SCHEMBL720006 | 0.73 | TP53 (0.34) | OPRM1HDAC6SLC6A2SLC6A3ABL1 | |
| SCHEMBL719577 | 0.73 | GCGR (0.37) | OPRM1HDAC6RCE1ABL1RIN1 | |
| SCHEMBL719013 | 0.73 | GCGR (0.37) | OPRM1HDAC6RCE1ABL1RIN1 | |
| SCHEMBL719941 | 0.72 | TEAD4 (0.39) | HDAC6RCE1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | OPRM1 4546/4885ALOX5 943/4885HDAC6 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.